We are an emerging leader with new solutions in the field of nuclear medicine technology

– Marking NorthStar expansion progress to increase U.S. production of non-highly enriched uranium produced molybdenum-99 (Mo-99), used in producing important medical isotope technetium-99m (Tc-99m) ‒ ‒ Recognizing RadioGenix® System contributions in addressing ongoing Mo-99 supply shortages by providing customers with nearly a year of continuous medical radioisotope supply since launch ‒ Beloit, Wis., October 14, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, announced that it hosted a ribbon-cutting, groundbreaking and speakers event, “Molybdenum-99: Domestic Radioisotope Production Now, Expansion for the Future,” at its headquarters in Beloit, Wis.

‒ Panel to discuss domestic Tc-99m radioisotope production, role of nuclear diagnostics and treatments in advancing personalized medicine – BELOIT, Wis.

Beloit, Wis. and W. Lafayette, Ind., August 20, 2019 – NorthStar Medical Radioisotopes, LLC and Purdue University’s College of Pharmacy today announced a collaborative agreement which expands the College of Pharmacy’s nuclear pharmacy training program.